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Introduction {#jth14378-sec-0008}
============

Trauma‐induced coagulopathy (TIC) develops in up to 25% of severely injured trauma patients, aggravates massive hemorrhage, and is associated with increased mortality [1](#jth14378-bib-0001){ref-type="ref"}, [2](#jth14378-bib-0002){ref-type="ref"}. Current resuscitation practices often include an empirical balanced resuscitation approach with administration of red blood cells (RBCs), plasma and platelets (PLTs) in a 1 : 1 : 1 ratio [3](#jth14378-bib-0003){ref-type="ref"}, [4](#jth14378-bib-0004){ref-type="ref"}, [5](#jth14378-bib-0005){ref-type="ref"}. Although this non‐specific strategy reduces the development of dilutional coagulopathy, it may not correct different pre‐existing forms of coagulopathy that are present in individual patients [6](#jth14378-bib-0006){ref-type="ref"}, [7](#jth14378-bib-0007){ref-type="ref"}. Also, this empirical approach fails to correct TIC in recipients of large volumes of blood [8](#jth14378-bib-0008){ref-type="ref"}, [9](#jth14378-bib-0009){ref-type="ref"}. Implementation of the empirical 1 : 1 : 1 strategy, often as part of massive transfusion protocols, has increased the amount of blood products transfused [10](#jth14378-bib-0010){ref-type="ref"}. As transfusion is also associated with adverse outcomes, including infections [11](#jth14378-bib-0011){ref-type="ref"} and organ failure [12](#jth14378-bib-0012){ref-type="ref"}, [13](#jth14378-bib-0013){ref-type="ref"}, [14](#jth14378-bib-0014){ref-type="ref"}, [15](#jth14378-bib-0015){ref-type="ref"}, the outcome of traumatic bleeding is probably optimal with a targeted, precision‐medicine approach to the management of TIC, leading to improved outcomes while avoiding unnecessary transfusion.

This precision approach requires monitoring of the effects of therapy. Clotting tests, such as prothrombin time, activated partial thromboplastin time, and PLT count, have limited usefulness in guiding resuscitation strategy [16](#jth14378-bib-0016){ref-type="ref"}, [17](#jth14378-bib-0017){ref-type="ref"}, [18](#jth14378-bib-0018){ref-type="ref"}. Viscoelastic hemostatic assays (VHAs), such as thrombelastography (TEG) and rotational thromboelastometry (ROTEM), are rapid tests that can identify TIC in trauma patients [19](#jth14378-bib-0019){ref-type="ref"}, [20](#jth14378-bib-0020){ref-type="ref"}, [21](#jth14378-bib-0021){ref-type="ref"}. A trial in which trauma patients were randomized to either TEG or conventional tests to guide laboratory‐based transfusion therapy showed a survival benefit for the TEG‐guided arm, while the amount of blood products needed was decreased [22](#jth14378-bib-0022){ref-type="ref"}. These results are promising, although the effects need to be validated in larger multicenter trials. Also, the response of VHA parameters to therapy given during bleeding is not known. Therefore, existing algorithms only provide threshold levels that trigger therapy [22](#jth14378-bib-0022){ref-type="ref"}, [23](#jth14378-bib-0023){ref-type="ref"}, [24](#jth14378-bib-0024){ref-type="ref"}, [25](#jth14378-bib-0025){ref-type="ref"}. In order to identify effective therapy for TIC, algorithms based on VHA parameters need to be refined. The aim of this study was to determine the response of ROTEM parameters to therapy in bleeding trauma patients.

Methods {#jth14378-sec-0009}
=======

As part of a prospective multicenter observational study, termed the Activation of Coagulation and Inflammation in Trauma study (United Kingdom Clinical Research Network Study Portfolio, ID: 5637), this study was performed in six European level 1 trauma centers, i.e. London, Oslo, Copenhagen, Oxford, Cologne, and Amsterdam, which are members of the International Trauma Research Network (INTRN). All adult trauma patients (aged ≥ 18 years) who required full trauma team activation, who received at least 4 units of RBCs within 24 h, and who were still alive after 24 h, were recruited between January 2008 and April 2015. Patients who received \> 2 L of intravenous fluids prior to arrival at the hospital, who arrived in the emergency department (ED) \> 2 h after injury, who were transferred from other hospitals and who had burns covering \> 5% of the total body surface area were not eligible. Patients were retrospectively excluded if they declined to give informed consent, were taking anticoagulant medications other than aspirin (\< 650 mg daily), had moderate or severe liver disease (Child\'s classification B or C3), had a known bleeding diathesis, had no ROTEM measurements available, or died within 24 h post‐injury.

Written informed consent was obtained from each patient. When the patient was unconscious, written informed consent was obtained from a legal representative. This study was conducted according to the Statement of the Declaration of Helsinki, and was performed after approval by the local ethics committees.

The following data were collected prospectively and placed in a centralized database: data on patient demographics, time of injury, trauma mechanism, vital signs and laboratory test results up to 24 h post‐injury, Injury Severity Score (ISS), Abbreviated Injury Scale score, 24‐h and 28‐day mortality, total fluids (crystalloids, colloids, and hypertonic saline), amount of RBC units, plasma and PLT units, and antifibrinolytic (tranexamic acid \[TXA\]) and procoagulant agents (fibrinogen concentrates and cryoprecipitate).

Blood sampling and ROTEM assays {#jth14378-sec-0010}
-------------------------------

Blood was drawn and collected in citrated tubes immediately on arrival at the ED and at 24 h post‐injury. Additionally, during resuscitation with blood component therapy, blood samples were drawn after administration of 4, 8 and 12 RBC units. The dose of plasma and PLTs given in the intervals between blood draws was also prospectively collected. Two ROTEM assays (EXTEM and FIBTEM) were performed by trained personnel after blood samples were taken. These assays were chosen on the basis of our previous results obtained when we were determining threshold values for TIC [26](#jth14378-bib-0026){ref-type="ref"}. Within each assay, six ROTEM parameters were analyzed: the clotting time (CT), the clot amplitude after 5 min (CA5), the clot amplitude after 10 min, the angle of tangent at 20‐mm amplitude (*α* angle), the maximum clot firmness, and the lysis index of the clot after 30 min (LY30).

In this same patient cohort, we recently determined ROTEM thresholds with a high detection rate for TIC, as measured on ED arrival [26](#jth14378-bib-0026){ref-type="ref"}. FIBTEM CA5 had the highest diagnostic performance in detecting a low fibrinogen level (\< 2.0 g dL^−1^), with a cut‐off value of \< 10 mm. EXTEM‐FIBTEM CA5 had the highest diagnostic performance in detecting a low PLT count (\< 100 × 10^9^ L^−1^), with a threshold of 30 mm. EXTEM LY30 below 85% was associated with sudden increases in RBC requirements and mortality. EXTEM ca5 had the highest diagnostic performance in detecting coagulopathy, as defined by an International Normalized Ratio (INR) of \> 1.2, with a CA5 threshold of 40 mm. The response of ROTEM parameters to treatment was investigated in all bleeding patients, as well as in those patients with a ROTEM profile corresponding to TIC upon ED arrival. The number of PLT units was corrected for the number of pooled donors, as this differs between centers.

The effect of plasma and PLT therapy on ROTEM parameters was analyzed by relating the therapy given within a time interval to changes in ROTEM results in the following measurement. These intervals are the baseline to 4 RBC units time point, the 4 RBC units to 8 RBC units time point, and the 8 RBC units to 12 RBC units time point. This approach was chosen because VHA parameters change rapidly in response to blood products. To describe the effects of TXA and fibrinogen products on ROTEM VHA profiles, the change between baseline and 24‐h measurements was used. Intervals in which a ROTEM value was missing, and the change for ROTEM values could therefore not be calculated, were left out. This resulted in a variable amount of intervals that could be evaluated. There was no loss of data regarding the 28 day mortality. Other outcome data were not gathered, as the denominator of measurements comprises intervals and not patients.

Transfusion strategy {#jth14378-sec-0011}
--------------------

In all trauma centers, issuing of blood products, antifibrinolytic agents and procoagulant agents by the blood bank was performed through locally implemented massive transfusion protocols (MTPs). In most centers, the MTP was activated for patients with a systolic blood pressure of \< 90 mmHg and with an inadequate response to fluid administration, and for whom there was a suspicion of ongoing bleeding. Centers empirically applied blood products in a fixed ratio. Administration of TXA, followed by continuous infusion for a period of 8 h, was used as a principal component of the MTP in all centers. Cryoprecipitate was used in London, Oxford, and Copenhagen, and fibrinogen concentrates were used in Oslo, Cologne, and Amsterdam. The trigger for use of these concentrated fibrinogen products differed between centers, from a fibrinogen level of ≤ 1.0 g L^−1^ to a fibrinogen level of ≤ 2.0 g L^−1^. Centers had a restrictive approach to the use of fluids, but there was no shared protocol on fluid management. Differences in protocols have been described previously [27](#jth14378-bib-0027){ref-type="ref"}.

Statistics {#jth14378-sec-0012}
----------

Sample size was not prespecified in this exploratory study, as ROTEM responses to therapy have not been described before. Patient characteristics and ROTEM values are given in the tables, and expressed as mean and standard deviation (SD) if normally distributed; non‐normally distributed data are expressed as median and interquartile ranges. Categorical data are presented as frequencies and percentages. To test for differences in patient characteristics and ROTEM profiles, Student\'s *t*‐test and Mann--Whitney *U*‐tests were used. Categorical variables were compared by use of the chi‐square test. For multiple comparisons, a one‐way [anova]{.smallcaps} was used. A *P*‐value of \< 0.05 was considered to be statistically significant.

Results {#jth14378-sec-0013}
=======

In total, 309 patients for whom ROTEM profiles were available were transfused with ≥ 4 RBC units (their characteristics are shown in Table [1](#jth14378-tbl-0001){ref-type="table"}). Most patients had sustained a blunt trauma, were in shock, and were coagulopathic, as reflected by a prolonged mean INR and decreased levels of fibrinogen. The mean baseline ROTEM variables were mostly within the reference values as provided by the manufacturer (Table [2](#jth14378-tbl-0002){ref-type="table"}). All measurements together yielded 426 time intervals in which the effect of transfusion strategy on the ROTEM profiles could be determined, although the amount of intervals available for analysis varied per treatment and per test.

###### 

Baseline characteristics and outcome of patients receiving ≥ 4 red blood cell units

                                   *N* = 309 (SD)
  -------------------------------- ----------------
  Age (years)                      44.8 (1.1)
  Male gender (%)                  73
  Trauma mechanism, blunt (%)      83
  ISS                              29.1 (0.7)
  SBP (mmHg)                       106.2 (1.9)
  Heart rate (beats min^--1^)      110.2 (1.7)
  Lactate (mmol L^−1^)             5.1 (4.4)
  GCS                              10.8 (0.3)
  Hb (g dL^−1^)                    12.5 (0.1)
  Platelet count (× 10^9^ L^−1^)   214.2 (4.1)
  INR                              1.22 (0.1)
  Fibrinogen (g L^−1^)             1.9 (0.1)
  Base excess (mEq L^--1^)         − 7.5 (0.4)
  28‐day mortality (%)             22.9

GCS, Glasgow Coma Score; Hb, hemoglobin; INR, International Normalized Ratio; ISS, Injury Severity Score; SBP, systolic blood pressure.

John Wiley & Sons, Ltd

###### 

Baseline rotational thromboelastometry variables of patients receiving ≥ 4 red blood cell units

                         *N* = 309
  ---------------------- --------------
  EXTEM CT (s)           70.3 (2.0)
  EXTEM CA5 (mm)         39.7 (0.6)
  EXTEM CA10 (mm)        49.6 (0.7)
  EXTEM MCF (mm)         58.5 (0.6)
  EXTEM *α* angle (°)    67.9 (0.6)
  EXTEM LY30 (%)         96.9 (1.0)
  EXTEM CFT (s)          136.4 (10.9)
  FIBTEM CA5 (mm)        10.0 (0.3)
  FIBTEM CA10 (mm)       10.9 (0.3)
  FIBTEM MCF (mm)        12.7 (0.4)
  FIBTEM *α* angle (°)   61.7 (0.5)
  FIBTEM LY30 (%)        94.9 (1.0)

CA5, clot amplitude after 5 min; CA10, clot amplitude after 10 min; CFT, clot formation time; CT, clotting time; LY30, lysis index of the clot after 30 min; MCF, maximum clot firmness. Data are mean and standard error of the mean.

John Wiley & Sons, Ltd

ROTEM response to treatment with fibrinogen {#jth14378-sec-0014}
-------------------------------------------

Of the 309 patients, 119 (39%) received fibrinogen products, containing a mean of 3.8 g (SD 1.2 g) of fibrinogen. Patients given fibrinogen products were more severely injured, as reflected by a higher ISS, and more acidotic than those not receiving fibrinogen (Table [S1](#jth14378-sup-0001){ref-type="supplementary-material"}). Also, baseline fibrinogen levels were lower in patients receiving fibrinogen. Despite this, in the whole group of patients receiving fibrinogen, administration of fibrinogen products resulted in a greater increase in FIBTEM parameters than in patients not receiving fibrinogen (Table [3](#jth14378-tbl-0003){ref-type="table"}). In patients with a ROTEM profile known to correspond with a low fibrinogen level (FIBTEM CA5 \< 10 mm) [26](#jth14378-bib-0026){ref-type="ref"}, the response to therapy was the same as in the whole cohort receiving fibrinogen.

###### 

Rotational thromboelastometry (ROTEM) response to fibrinogen

                         All patients receiving fibrinogen                         Patients with FIBTEM CA5 \< 10 receiving fibrinogen       Patients not receiving fibrinogen
  ---------------------- --------------------------------------------------------- --------------------------------------------------------- -----------------------------------
  FIBTEM CA5 (mm)        5.0 (3.9--6.1)[\*](#jth14378-note-0006){ref-type="fn"}    5.1 (3.8--6.4)[\*](#jth14378-note-0006){ref-type="fn"}    2.4 (1.5--3.3)
  FIBTEM CA10 (mm)       5.5 (4.2--6.8)[\*](#jth14378-note-0006){ref-type="fn"}    5.5 (4.1--7.0)[\*](#jth14378-note-0006){ref-type="fn"}    2.8 (1.8--3.7)
  FIBTEM MCF (mm)        5.8 (4.1--7.4)[\*](#jth14378-note-0006){ref-type="fn"}    5.8 (3.8--7.9)[\*](#jth14378-note-0006){ref-type="fn"}    2.1 (0.8--3.6)
  FIBTEM *α* angle (°)   8.4 (5.3--11.6)[\*](#jth14378-note-0006){ref-type="fn"}   8.4 (5.4--11.4)[\*](#jth14378-note-0006){ref-type="fn"}   3.2 (1.0--5.5)

CA5, clot amplitude after 5 min; CA10, clot amplitude after 10 min; Data are median and interquartile range (IQR); MCF, maximum clot firmness. \**P* \< 0.05 versus not receiving fibrinogen. ROTEM response was determined in the interval between baseline and *t* = 24 h.

John Wiley & Sons, Ltd

ROTEM response to treatment with platelets {#jth14378-sec-0015}
------------------------------------------

Of the 309 patients, 212 (69%) received PLTs. Patients given PLTs had lower baseline platelet counts than those not receiving PLTs, although the PLT count was normal in most patients (Table [S2](#jth14378-sup-0001){ref-type="supplementary-material"}). In all patients, EXTEM parameters of clot formation worsened during the course of bleeding and treatment (Table [4](#jth14378-tbl-0004){ref-type="table"}). In the whole group of patients receiving PLTs, EXTEM values were higher during management than in those not receiving PLTs, although the difference did not reach statistical significance. In patients with a ROTEM profile known to correspond to low PLT levels [26](#jth14378-bib-0026){ref-type="ref"}, the decrease in EXTEM ca5 was significantly less than in those not receiving therapy.

###### 

Rotational thromboelastometry (ROTEM) response to platelets

                        All patients receiving platelets   Patients with EXTEM ca5 -- FIBTEM CA5 \< 30 receiving platelets   Patients not receiving platelets
  --------------------- ---------------------------------- ----------------------------------------------------------------- ----------------------------------
  EXTEM ca5 (mm)        − 1.55 (− 4.48 to 1.37)            0.74 (− 4.77 to 6.25)[\*](#jth14378-note-0007){ref-type="fn"}     − 4.39 (− 6.06 to − 2.72)
  EXTEM CA10 (mm)       − 1.14 (− 4.24 to 1.95)            0.53 (− 5.6 to 6.66)                                              − 4.13 (− 5.96 to − 2.3)
  EXTEM MCF (mm)        − 0.11 (− 2.77 to 2.55)            1.45 (− 3.92 to 6.81)                                             − 2.67 (− 4.58 to − 0.75)
  EXTEM *α* angle (°)   0.43 (− 2.96 to 3.82)              1.18 (− 5.8 to 8.16)                                              − 3.34 (− 5.07 to − 1.62)

CA5, clot amplitude after 5 min; CA10, clot amplitude after 10 min; Data are median and interquartile range (IQR); MCF, maximum clot firmness. \**P* \< 0.05 versus not receiving platelets. ROTEM response was determined in intervals during resuscitation therapy.

John Wiley & Sons, Ltd

ROTEM response to treatment with plasma {#jth14378-sec-0016}
---------------------------------------

Of the 309 patients, 280 (91%) received plasma. The patients receiving plasma were more shocked, as reflected by a higher heart rate and lower base excess (Table [S3](#jth14378-sup-0001){ref-type="supplementary-material"}). In the whole group of patients receiving plasma, plasma transfusion significantly reduced EXTEM CT, with a mean of 3.1 s, as compared with patients not receiving plasma (Table [5](#jth14378-tbl-0005){ref-type="table"}), in whom EXTEM CT was prolonged during bleeding and management. In those patients with an EXTEM CT known to correspond to coagulopathy, ROTEM responses to therapy were more pronounced, with an EXTEM CT reduction of 10.6 s, although statistical significance was not reached, owing to a wide confidence interval. It is of note that the amount of intervals was small.

###### 

Rotational thromboelastometry (ROTEM) response to plasma

                   All patients receiving plasma                                   Patients with EXTEM CT \> 80 and CA5 \> 40 receiving plasma   Patients not receiving plasma
  ---------------- --------------------------------------------------------------- ------------------------------------------------------------- -------------------------------
  EXTEM CT (s)     − 3.1 (− 10.0 to 3.9)[\*](#jth14378-note-0008){ref-type="fn"}   − 10.6 (− 45.7 to 24.2)                                       10.8 (− 0.8 to 22.3)
  EXTEM MCF (mm)   − 1.7 (− 3.3 to − 0.1)                                          − 5.2 (− 12.1 to 1.7)                                         − 4.1 (− 7.9 to − 0.4)
  EXTEM CFT (s)    19.5 (4.7--34.3)                                                30.31 (1.2--59.4)                                             37.4 (5.4--69.4)

CT, clotting time; CFT, clot formation time; Data are median and interquartile range (IQR); MCF, maximum clot firmness. *P* \< 0.05 versus not receiving plasma. ROTEM response was determined in intervals during resuscitation therapy.

John Wiley & Sons, Ltd

ROTEM response to treatment with TXA {#jth14378-sec-0017}
------------------------------------

Use of TXA was not registered in 19 patients. Of the remaining 290 patients, 112 (39%) received TXA. Patients given TXA were more severely injured, as reflected by a higher ISS, and were more shocked and more acidotic than those not receiving TXA (Table [S4](#jth14378-sup-0001){ref-type="supplementary-material"}). In the whole group of patients receiving TXA, administration of TXA resulted in greater improvements in lysis and FIBTEM parameters than in patients not receiving TXA (Table [6](#jth14378-tbl-0006){ref-type="table"}). In those patients with a LY30 suggestive of hyperfibrinolysis [26](#jth14378-bib-0026){ref-type="ref"}, the response to therapy was the same as in the whole cohort receiving TXA.

###### 

Rotational thromboelastometry (ROTEM) response to tranexamic acid (TXA)

                         All patients receiving TXA                                Patients with EXTEM LY30 \< 85% receiving TXA             Patients not receiving TXA
  ---------------------- --------------------------------------------------------- --------------------------------------------------------- ----------------------------
  EXTEM LY30 (%)         5.4 (4.3--6.5)[\*](#jth14378-note-0009){ref-type="fn"}    5.4 (4.1--6.7)[\*](#jth14378-note-0009){ref-type="fn"}    3.0 (2.1--3.9)
  FIBTEM CA5 (mm)        6.0 (4.8--7.3)[\*](#jth14378-note-0009){ref-type="fn"}    6.1 (4.6--7.5)[\*](#jth14378-note-0009){ref-type="fn"}    3.6 (2.6--4.5)
  FIBTEM CA10 (mm)       6.1 (4.4--7.9)[\*](#jth14378-note-0009){ref-type="fn"}    6.1 (3.6--8.6)[\*](#jth14378-note-0009){ref-type="fn"}    3.2 (1.7--4.6)
  FIBTEM MCF (mm)        8.1 (5.3--10.9)[\*](#jth14378-note-0009){ref-type="fn"}   8.1 (5.0--11.2)[\*](#jth14378-note-0009){ref-type="fn"}   3.3 (0.8--5.8)
  FIBTEM *α* angle (°)   5.4 (4.4--6.5)[\*](#jth14378-note-0009){ref-type="fn"}    5.4 (4.1--6.7)[\*](#jth14378-note-0009){ref-type="fn"}    3.0 (2.1--3.9)
  FIBTEM LY30 (%)        6.0 (4.8--7.3)[\*](#jth14378-note-0009){ref-type="fn"}    6.0 (4.5--7.5)[\*](#jth14378-note-0009){ref-type="fn"}    3.6 (2.6--4.5)

CA5, clot amplitude after 5 min; CA10, clot amplitude after 10 min; LY30, lysis index of the clot after 30 min; Data are median and interquartile range (IQR); MCF, maximum clot firmness. \**P* \< 0.05 versus not receiving TXA. ROTEM response was determined in the interval between baseline and *t* = 24 h.

John Wiley & Sons, Ltd

Discussion {#jth14378-sec-0018}
==========

The results indicate that, during management of patients with traumatic bleeding, almost all of the ROTEM profiles show further deterioration. This study suggests that the effect of treatment with transfusion products and procoagulant therapy with the aim of improving deranged ROTEM parameters can be monitored during traumatic hemorrhage. Fibrinogen, plasma, PLTs and TXA improve ROTEM parameters of clot formation and firmness, and decrease clot lysis. Although the effects can be described as modest, it must be noted that these improvements were detected during ongoing resuscitation of patients who were actively bleeding. In the subgroup of patients with ROTEM threshold values that were previously identified to correspond to coagulopathy (i.e. low fibrinogen levels, thrombocytopenia, increased fibrinolysis, and/or an INR of \> 1.2), the efficacy of plasma and PLTs in correcting ROTEM parameters was possibly more robust than in the whole bleeding population receiving treatment.

We previously showed that, in the same cohort of patients, administration of fibrinogen did not result in correction of low fibrinogen levels in patients who are actively bleeding [28](#jth14378-bib-0028){ref-type="ref"}. Here, we show that a mean dose of fibrinogen of 3.8 g improves EXTEM ca5 levels by 5 mm. Therefore, this ROTEM marker may guide fibrinogen dosing in patients with traumatic bleeding. Notably, it was shown previously that low fibrinogen levels are associated with adverse outcomes in patients with traumatic hemorrhage [29](#jth14378-bib-0029){ref-type="ref"}, [30](#jth14378-bib-0030){ref-type="ref"}, [31](#jth14378-bib-0031){ref-type="ref"}. Unfortunately, we cannot provide further analysis of the effect of fibrinogen dose on correction of ROTEM parameters, because the exact timing of fibrinogen administration was not noted.

For monitoring of the effect of TXA, there are currently no conventional clotting tests available at the bedside. In this study, 1 g of TXA improved all early markers of clot formation, and decreased markers of lysis. It was shown previously that TXA administration is associated with a good outcome [28](#jth14378-bib-0028){ref-type="ref"}. Taken together, the results indicate that monitoring of the effect of procoagulant therapy on TIC is possible during the management of bleeding trauma patients.

Plasma transfusion reduced EXTEM CT, whereas, in patients not receiving plasma, EXTEM CT was further prolonged during bleeding. As EXTEM CT is a marker of TIC that occurs very early during ROTEM testing, the results suggest that EXTEM CT may guide the specific need for an increased dose of plasma. Note that, as low fibrinogen levels affect the whole coagulation process, and fibrinogen will also reduce EXTEM CT, one may first consider correcting a fibrinogen deficiency with fibrinogen concentrates prior to considering additional plasma.

In severe injury, a drop in the PLT count occurs late [32](#jth14378-bib-0032){ref-type="ref"}. Therefore, the PLT count as such may not be a useful transfusion trigger. In this study, in which most patients had normal PLT counts, the derangement of EXTEM parameters of clot formation was less pronounced in patients receiving PLT transfusion, which may suggest that EXTEM parameters are more useful then PLT counts in monitoring effects of therapy.

Previously, in the same cohort of patients, threshold ROTEM values corresponding to TIC and adverse outcomes were identified [26](#jth14378-bib-0026){ref-type="ref"}. With these values, algorithms for guidance of the management of patients with TIC were constructed. The aim of this study was to provide follow‐up data. Here, we show that, in bleeding patients, transfusion of plasma and PLTs in those patients with ROTEM levels that would trigger therapy according to threshold values corresponding to TIC [26](#jth14378-bib-0026){ref-type="ref"} resulted in more improvement of ROTEM values than in the whole group of bleeding patients. However, the effect of plasma did not reach statistical significance, probably because of a loss of data points. Whether use of the algorithm to guide therapy results in better outcomes while reducing unnecessary transfusion is currently under investigation in a randomized controlled trial [33](#jth14378-bib-0033){ref-type="ref"}.

Limitations of this study should be acknowledged. Studies were performed in patients with ongoing bleeding, in whom the rate of bleeding most likely affected ROTEM results, but this is impossible to account for. Another issue is that blood products were administered together, making it impossible to attribute an effect on ROTEM values to a specific therapy. However, these issues reflects real‐life clinical practice. Another important limitation is that we were not able to report on ROTEM changes in response to different doses of fibrinogen and TXA. This remains an area that needs to be explored. Also, exsanguinating patients were excluded, in order to provide for follow‐up samples. Therefore, the results may not apply to the most severely bleeding patients. Also, as most patients in this study had sustained blunt injuries, it remains to be determined whether the response to therapy is the same in patients with penetrating injury. Finally, transfusion protocols differ between centers, which is a limitation of this observational study.

Conclusion {#jth14378-sec-0019}
==========

VHAs such as ROTEM can be used for monitoring of treatment for TIC during ongoing traumatic hemorrhage. In patients with ROTEM threshold values known to correspond to coagulopathy, the efficacy of plasma and PLTs was possibly clearer than in the whole bleeding population, suggesting that ROTEM‐based algorithms can be used to treat and monitor TIC.
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